Renee Rojas
Family · West Deptford, NJNPI 1164150116
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 234 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,042 and has fallen 63.4% since, to $746 in 2025. Among family clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 234 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$791
- Novo Nordisk$518
- AstraZeneca$357
- Lilly USA, LLC$334
- Axsome Therapeutics, Inc.$321
- Pfizer$268
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,980100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 52 | $791 |
| Novo Nordisk | 34 | $518 |
| AstraZeneca | 13 | $357 |
| Lilly USA, LLC | 21 | $334 |
| Axsome Therapeutics, Inc. | 17 | $321 |
| Pfizer | 15 | $268 |
| GSK | 16 | $253 |
| Idorsia Pharmaceuticals US Inc | 14 | $194 |
| Exact Sciences | 8 | $192 |
| Amgen | 6 | $94 |
| Otsuka America Pharmaceutical, Inc. | 5 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $69 |
| Johnson & Johnson | 4 | $65 |
| Bausch Health US, LLC | 3 | $59 |
| Supernus Pharmaceuticals, Inc. | 3 | $52 |
| Indivior Inc. | 3 | $50 |
| Impel Pharmaceuticals Inc. | 2 | $49 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Alkermes, Inc. | 2 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Almatica Pharma LLC | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,980 in reported general payments places this provider in the 90th percentile of 2,692 family providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 43 | $45,450 |
| MounjaroTirzepatide | 26 | $36,018 |
| VraylarCariprazine Hcl | 16 | $25,211 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $16,431 |
| PaxlovidNirmatrelvir/Ritonavir | 11 | $1,429 |
| Atorvastatin Calcium | 79 | $1,326 |
| Losartan Potassium | 45 | $756 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $721 |
| Amlodipine Besylate | 86 | $640 |
| Metoprolol Succinate | 24 | $599 |
| Lisinopril | 57 | $545 |
| Ezetimibe | 18 | $541 |
| Rosuvastatin Calcium | 34 | $527 |
| Levothyroxine Sodium | 59 | $491 |
| Pantoprazole Sodium | 27 | $485 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $518 | $45,45043 claims |
| Lilly USA, LLCMounjaro | $334 | $36,01826 claims |
| AbbVieVraylar, Synthroid | $791 | $25,40027 claims |
| GSKTrelegy Ellipta | $253 | $16,43117 claims |
| PfizerPaxlovid | $268 | $1,42911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,692 family providers in New Jersey.
Other family in West Deptford
- Jennifer DemaioMorristown$412K
- Kara TrlicaCranbury$186K
- Nicole BauerParamus$161K
- China BattistaWall Township$142K
- Nancy EisenbergerVoorhees$82K
- Jennifer AbitabiloGlen Ridge$54K
- Megan FiloramoMorristown$53K
- Shawn DenningToms River$29K
- Kimberly ClementeEatontown$25K
- Toni Michelle SeibertColumbus$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.